Rtw Investments, LP’s Celldex Therapeutics Inc New Position
Does Rtw Investments, LP own Celldex Therapeutics Inc New (TCE2)? Not currently — the last reported position was 3.46M shares worth $137M in Q4 2023; the fund’s latest 13F (Q1 2026) no longer reports it.
Position Value
$137M
Q4 2023
Shares
3.46M
% of Portfolio
+2.15%
Quarters Held
15
position exited
Position History TCE2
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q4 2023 | 3.46M | $137M | +2.15% |
| Q3 2023 | 3.46M | $95M | +2.01% |
| Q2 2023 | 3.46M | $118M | +2.24% |
| Q1 2023 | 3.08M | $111M | +2.31% |
| Q4 2022 | 3.08M | $137M | +2.81% |
| Q3 2022 | 3.08M | $87M | +2.00% |
| Q2 2022 | 3.08M | $83M | +2.15% |
| Q1 2022 | 3.08M | $105M | +2.17% |
| Q4 2021 | 3.92M | $152M | +2.21% |
| Q3 2021 | 3.91M | $211M | +3.18% |
| Q2 2021 | 3.91M | $131M | +1.97% |
| Q1 2021 | 3.91M | $81M | +1.26% |
| Q4 2020 | 3.42M | $60M | +1.01% |
| Q3 2020 | 3.12M | $46M | +1.11% |
| Q2 2020 | 2.61M | $34M | +0.95% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Rtw Investments, LP’s full portfolio or all institutional holders of TCE2.